Cardax to Lead Plenary Session at Regenerative Medicine Conference

Link Between Inflammation, Chronic Disease, and Aging Highlighted

HONOLULU, Nov. 6, 2017 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) announced today that it will lead the opening Plenary Session and participate in other key presentations at the opening session of Pacific Regenerative Medicine Conference being held November 6-7, 2017 in Honolulu, Hawaii.

The Plenary Session is titled "The Emerging Role of Anti-Inflammatory Treatment Modalities in Chronic Disease and Aging," is certified as continuing medical education (CME) for physicians, and will feature the following speakers and topics:

  • Jon L. Ruckle, MD, Cardax acting Chief Medical Officer and clinical trial consultant
    • Topic: Inflammation and Cardiovascular Disease Risk
  • Gilbert M. Rishton, PhD, Cardax Chief Science Officer
    • Topic: Possible Anti-Inflammatory Modalities for Cardiovascular Health
  • Bradley J. Willcox, MD, Cardax collaborative researcher and consultant
    • Topic: Inflammaging: The Link Between Inflammation, Cardiovascular Disease, and Aging

Cardax CEO David G. Watumull will also participate in a panel discussion: "What Medical Tourism Means to a Local Economy."

"Our participation in this conference aligns well with our strategy to raise awareness within the medical community of the need for safe anti-inflammatory strategies to optimize health and longevity," said Cardax CEO David G. Watumull. "It also demonstrates the global role Hawaii can play as a Center of Excellence for inflammatory health and anti-aging."

The conference is being held at the Hawaii Convention Center and more information can be found at: Cardax helped organize the conference and is a Platinum Sponsor.

About Cardax
Cardax devotes substantially all of its efforts to developing and commercializing safe anti-inflammatory dietary supplements and drugs. Cardax is initially focusing on astaxanthin, which is a powerful and safe naturally occurring anti-inflammatory without the side effects of currently marketed anti-inflammatories. The safety and efficacy of Cardax's products have not been directly evaluated in clinical trials or confirmed by the FDA.

Media and Investors
Janice Kam

Safe Harbor
This release may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of our company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Some of the factors that could cause our actual results to differ from our expectations or beliefs include, without limitation, the risks discussed from time to time in our filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, we undertake no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.


View original content with multimedia:

SOURCE Cardax, Inc.